{
  "source": "PA-Notification-Idiopathic-Pulmonary-Fibrosis-Esbriet-Ofev.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Name 2025 P 1147-13\nProgram Prior Authorization/Notification\nMedications Esbriet® (pirfenidone)*and Ofev® (nintedanib)\nP&T Approval Date 11/2014, 11/2015, 9/2016, 9/2017, 9/2018, 9/2019, 10/2019, 4/2020,\n4/2021, 4/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nEsbriet (pirfenidone)* is a pyridone and Ofev (nintedanib) is a kinase inhibitor that are indicated\nfor the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is also indicated for slowing the\nrate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial\nlung disease (SSc-ILD) and for the treatment of chronic fibrosing interstitial lung diseases\n(ILDs) with a progressive phenotype.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Idiopathic pulmonary fibrosis\n1. Initial Authorization\na. Esbriet* and Ofev will be approved based on the following criterion:\n(1) Diagnosis of idiopathic pulmonary fibrosis\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Esbriet* will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Esbriet therapy\nb. Ofev will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Ofev therapy\nAuthorization will be issued for 12 months\nB. Systemic sclerosis-associated interstitial lung disease (Ofev only)\n1. Initial Authorization\na. Ofev will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) Diagnosis of systemic sclerosis-associated interstitial lung disease\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Ofev will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Ofev therapy\nAuthorization will be issued for 12 months\nC. Chronic fibrosing interstitial lung disease with a progressive phenotype (Ofev only)\n1. Initial Authorization\na.",
    "ositive clinical response to Ofev therapy\nAuthorization will be issued for 12 months\nC. Chronic fibrosing interstitial lung disease with a progressive phenotype (Ofev only)\n1. Initial Authorization\na. Ofev will be approved based on the following criterion:\n(1) Diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive\nphenotype\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Ofev will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Ofev therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Brand Esbriet is typically excluded from coverage. Tried/Failed criteria may be in place. Please\nrefer to plan specifics to determine exclusion status.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Esbriet [Prescribing Information]. Genentech USA, Inc. South San Francisco, CA. February\n2023.\n© 2025 UnitedHealthcare Services, Inc.\n2\n2. Ofev [Prescribing Information]. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT.\nOctober 2024.\nProgram Prior Authorization/Notification - Esbriet® (pirfenidone) and Ofev®\n(nintedanib)\nChange Control\n11/2014 New Program\n11/2015 Annual Review. No change to clinical content. Updated background.\n9/2016 Annual Review. No change in coverage criteria. Updated references.\n9/2017 Annual Review. No change in coverage criteria. Updated references.\n9/2018 Annual Review. No change in coverage criteria. Updated references.\n9/2019 Annual Review. N",
    "riteria. Updated references.\n9/2017 Annual Review. No change in coverage criteria. Updated references.\n9/2018 Annual Review. No change in coverage criteria. Updated references.\n9/2019 Annual Review. No change in coverage criteria. Updated references.\n10/2019 Added coverage criteria for systemic sclerosis for Ofev. Updated references.\n4/2020 Updated background and added Ofev coverage criteria for chronic fibrosing\ninterstitial lung diseases with a progressive phenotype. Updated reference.\n4/2021 Annual Review. No change in coverage criteria. Updated references.\n4/2022 Annual Review. No change in coverage criteria. Updated references.\n3/2023 Annual Review. Reformatted reauthorization criteria for Esbriet and Ofev for\nIdiopathic Pulmonary Fibrosis. Added exclusion footnote for Brand Esbriet.\nAdded state mandate footnote and updated references.\n3/2024 Annual review. No change in coverage criteria. Updated references.\n3/2025 Annual review. No change in coverage criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}